JP2002542188A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542188A5 JP2002542188A5 JP2000611904A JP2000611904A JP2002542188A5 JP 2002542188 A5 JP2002542188 A5 JP 2002542188A5 JP 2000611904 A JP2000611904 A JP 2000611904A JP 2000611904 A JP2000611904 A JP 2000611904A JP 2002542188 A5 JP2002542188 A5 JP 2002542188A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- pyridyl
- amine
- methylamine
- penten
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000034 method Methods 0.000 description 23
- 229910052739 hydrogen Inorganic materials 0.000 description 19
- 239000001257 hydrogen Substances 0.000 description 19
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 14
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 12
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- -1 hydrogen Chemical class 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 3
- 150000002431 hydrogen Chemical class 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 239000011593 sulfur Substances 0.000 description 3
- OKONKJZCUFNZOF-IWQZZHSRSA-N (z)-1,1,1-trifluoro-5-pyridin-3-ylpent-4-en-2-amine Chemical compound FC(F)(F)C(N)C\C=C/C1=CC=CN=C1 OKONKJZCUFNZOF-IWQZZHSRSA-N 0.000 description 2
- KRDMBTGZQZKPMM-XQRVVYSFSA-N (z)-1-pyridin-3-yloct-1-en-4-amine Chemical compound CCCCC(N)C\C=C/C1=CC=CN=C1 KRDMBTGZQZKPMM-XQRVVYSFSA-N 0.000 description 2
- DKYGQOACSMJSAU-PLNGDYQASA-N (z)-2-methyl-4-pyridin-3-ylbut-3-en-1-amine Chemical compound NCC(C)\C=C/C1=CC=CN=C1 DKYGQOACSMJSAU-PLNGDYQASA-N 0.000 description 2
- LRJBNZMEHQPINH-HYXAFXHYSA-N (z)-2-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CC(C)(N)C\C=C/C1=CC=CN=C1 LRJBNZMEHQPINH-HYXAFXHYSA-N 0.000 description 2
- MRIJAYUZKYDWER-CLFYSBASSA-N (z)-3-methyl-4-pyridin-3-ylbut-3-en-1-amine Chemical compound NCCC(/C)=C\C1=CC=CN=C1 MRIJAYUZKYDWER-CLFYSBASSA-N 0.000 description 2
- SMRNAYABIZGXAA-WAYWQWQTSA-N (z)-3-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CC(N)C(C)\C=C/C1=CC=CN=C1 SMRNAYABIZGXAA-WAYWQWQTSA-N 0.000 description 2
- CHDSWCRTHLGIKG-CLFYSBASSA-N (z)-4-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CC(N)C\C(C)=C/C1=CC=CN=C1 CHDSWCRTHLGIKG-CLFYSBASSA-N 0.000 description 2
- XSQFFUBHSNBOOI-NTMALXAHSA-N (z)-5-methyl-6-pyridin-3-ylhex-5-en-2-amine Chemical compound CC(N)CC\C(C)=C/C1=CC=CN=C1 XSQFFUBHSNBOOI-NTMALXAHSA-N 0.000 description 2
- DMKFUPLBEUFWTG-YFHOEESVSA-N (z)-5-methyl-6-pyridin-3-ylhex-5-en-3-amine Chemical compound CCC(N)C\C(C)=C/C1=CC=CN=C1 DMKFUPLBEUFWTG-YFHOEESVSA-N 0.000 description 2
- DVKLSFIDWUOOLI-UTCJRWHESA-N (z)-6-pyridin-3-ylhex-5-en-2-amine Chemical compound CC(N)CC\C=C/C1=CC=CN=C1 DVKLSFIDWUOOLI-UTCJRWHESA-N 0.000 description 2
- UBQUHVNXMNZXMC-HYXAFXHYSA-N (z)-6-pyridin-3-ylhex-5-en-3-amine Chemical compound CCC(N)C\C=C/C1=CC=CN=C1 UBQUHVNXMNZXMC-HYXAFXHYSA-N 0.000 description 2
- HHXVWPMGEAPFLJ-WAYWQWQTSA-N (z)-n,2-dimethyl-4-pyridin-3-ylbut-3-en-1-amine Chemical compound CNCC(C)\C=C/C1=CC=CN=C1 HHXVWPMGEAPFLJ-WAYWQWQTSA-N 0.000 description 2
- CHTJZZLVNQDJDX-XQRVVYSFSA-N (z)-n,2-dimethyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CNC(C)(C)C\C=C/C1=CC=CN=C1 CHTJZZLVNQDJDX-XQRVVYSFSA-N 0.000 description 2
- NKGVBMWSNYPWCY-NTMALXAHSA-N (z)-n,3-dimethyl-4-pyridin-3-ylbut-3-en-1-amine Chemical compound CNCC\C(C)=C/C1=CC=CN=C1 NKGVBMWSNYPWCY-NTMALXAHSA-N 0.000 description 2
- YHQKIXRDSWTUJK-LUAWRHEFSA-N (z)-n,4-dimethyl-5-pyridin-3-ylpent-4-en-1-amine Chemical compound CNCCC\C(C)=C/C1=CC=CN=C1 YHQKIXRDSWTUJK-LUAWRHEFSA-N 0.000 description 2
- DBYGQAGUKUTJAX-NTMALXAHSA-N (z)-n,4-dimethyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CNC(C)C\C(C)=C/C1=CC=CN=C1 DBYGQAGUKUTJAX-NTMALXAHSA-N 0.000 description 2
- IERLPSICESFRNB-ALCCZGGFSA-N (z)-n,5-dimethyl-1-pyridin-3-ylhept-1-en-4-amine Chemical compound CCC(C)C(NC)C\C=C/C1=CC=CN=C1 IERLPSICESFRNB-ALCCZGGFSA-N 0.000 description 2
- HUGUNCUQATWKMX-LUAWRHEFSA-N (z)-n,5-dimethyl-6-pyridin-3-ylhex-5-en-2-amine Chemical compound CNC(C)CC\C(C)=C/C1=CC=CN=C1 HUGUNCUQATWKMX-LUAWRHEFSA-N 0.000 description 2
- TUDIQGZXIAJHPV-FLIBITNWSA-N (z)-n,5-dimethyl-6-pyridin-3-ylhex-5-en-3-amine Chemical compound CCC(NC)C\C(C)=C/C1=CC=CN=C1 TUDIQGZXIAJHPV-FLIBITNWSA-N 0.000 description 2
- JGGVBSFRKVZGAC-ALCCZGGFSA-N (z)-n-methyl-1-pyridin-3-yloct-1-en-4-amine Chemical compound CCCCC(NC)C\C=C/C1=CC=CN=C1 JGGVBSFRKVZGAC-ALCCZGGFSA-N 0.000 description 2
- IEVJOUFGBRDCNE-UTCJRWHESA-N (z)-n-methyl-5-pyridin-3-ylpent-4-en-2-amine Chemical compound CNC(C)C\C=C/C1=CC=CN=C1 IEVJOUFGBRDCNE-UTCJRWHESA-N 0.000 description 2
- RUUGQRVCWASUJC-DAXSKMNVSA-N (z)-n-methyl-6-pyridin-3-ylhex-5-en-2-amine Chemical compound CNC(C)CC\C=C/C1=CC=CN=C1 RUUGQRVCWASUJC-DAXSKMNVSA-N 0.000 description 2
- DOWXVOMJGXCXRP-XQRVVYSFSA-N (z)-n-methyl-6-pyridin-3-ylhex-5-en-3-amine Chemical compound CCC(NC)C\C=C/C1=CC=CN=C1 DOWXVOMJGXCXRP-XQRVVYSFSA-N 0.000 description 2
- LYIVXPJPEPNDIO-UHFFFAOYSA-N 3-(4-methoxyphenoxy)-n-methylpropan-1-amine Chemical compound CNCCCOC1=CC=C(OC)C=C1 LYIVXPJPEPNDIO-UHFFFAOYSA-N 0.000 description 2
- RLKHJESIHPCHGY-UHFFFAOYSA-N 3-[3-(methylamino)propoxy]aniline Chemical compound CNCCCOC1=CC=CC(N)=C1 RLKHJESIHPCHGY-UHFFFAOYSA-N 0.000 description 2
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- SORPQJVUFWZTTC-UHFFFAOYSA-N CC(C(C=C)C1=CC=CC=N1)N Chemical compound CC(C(C=C)C1=CC=CC=N1)N SORPQJVUFWZTTC-UHFFFAOYSA-N 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- QURLPTIXXSGZQG-UHFFFAOYSA-N n-methyl-3-pyridin-3-yloxypropan-1-amine Chemical compound CNCCCOC1=CC=CN=C1 QURLPTIXXSGZQG-UHFFFAOYSA-N 0.000 description 2
- IAOMYGPUHHWELN-UHFFFAOYSA-N n-methyl-4-pyridin-3-yloxybutan-2-amine Chemical compound CNC(C)CCOC1=CC=CN=C1 IAOMYGPUHHWELN-UHFFFAOYSA-N 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- PMOWTIHVNWZYFI-WAYWQWQTSA-N cis-2-coumaric acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1O PMOWTIHVNWZYFI-WAYWQWQTSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/295,181 US6166048A (en) | 1999-04-20 | 1999-04-20 | Pharmaceutical compositions for inhibition of cytokine production and secretion |
| US09/295,181 | 1999-04-20 | ||
| PCT/US2000/010551 WO2000062767A2 (en) | 1999-04-20 | 2000-04-20 | Pharmaceutical compositions containing pyridine or pyrimidine derivates for inhibition of cytokine production and secretion |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542188A JP2002542188A (ja) | 2002-12-10 |
| JP2002542188A5 true JP2002542188A5 (enExample) | 2007-06-14 |
Family
ID=23136585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000611904A Pending JP2002542188A (ja) | 1999-04-20 | 2000-04-20 | サイトカインの産生および分泌を阻害する製薬学的組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US6166048A (enExample) |
| EP (1) | EP1171127B1 (enExample) |
| JP (1) | JP2002542188A (enExample) |
| KR (1) | KR100816898B1 (enExample) |
| AT (1) | ATE304355T1 (enExample) |
| AU (1) | AU4471900A (enExample) |
| BR (1) | BR0009869A (enExample) |
| CA (1) | CA2370206C (enExample) |
| DE (1) | DE60022637T2 (enExample) |
| DK (1) | DK1171127T3 (enExample) |
| ES (1) | ES2251995T3 (enExample) |
| MX (1) | MXPA01010635A (enExample) |
| WO (1) | WO2000062767A2 (enExample) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6979695B2 (en) * | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20020052497A1 (en) * | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| CA2317572A1 (en) | 1998-04-02 | 1999-10-14 | Jared Miller Wagner | Pharmaceutical compositions and methods for use |
| US7790757B2 (en) * | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
| US20010031771A1 (en) | 1999-05-24 | 2001-10-18 | Gary Maurice Dull | Pharmaceutical compositions and methods for use |
| WO2000071520A2 (en) * | 1999-05-24 | 2000-11-30 | Targacept, Inc. | Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors |
| DE19956786A1 (de) * | 1999-11-25 | 2001-05-31 | Basf Ag | Verfahren zur Herstellung optisch aktiver Amine |
| US6656958B2 (en) | 2000-02-02 | 2003-12-02 | Abbott Laboratories | Substituted pyridine compounds useful for controlling chemical synaptic transmission |
| US20010034357A1 (en) * | 2000-02-02 | 2001-10-25 | Nan-Horng Lin | Substituted pyridine compounds useful for controlling chemical synaptic transmission |
| US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| US6610713B2 (en) | 2000-05-23 | 2003-08-26 | North Shore - Long Island Jewish Research Institute | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
| GB2381750A (en) * | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
| US7442546B2 (en) * | 2002-03-15 | 2008-10-28 | The Regents Of The University Of Michigan | Method of modulating inflammatory response |
| AU2003304297A1 (en) * | 2002-08-23 | 2005-01-21 | Sungho Jin | Article comprising gated field emission structures with centralized nanowires and method for making the same |
| US6987027B2 (en) | 2002-08-23 | 2006-01-17 | The Regents Of The University Of California | Microscale vacuum tube device and method for making same |
| AU2005225458B2 (en) | 2004-03-25 | 2008-12-04 | The Feinstein Institutes For Medical Research | Neural tourniquet |
| US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
| WO2005096992A1 (en) * | 2004-04-02 | 2005-10-20 | Arterial Remodelling Technologies, Inc. | Polymer-based stent assembly |
| ATE489132T1 (de) | 2004-12-27 | 2010-12-15 | The Feinstein Inst Medical Res | Behandlung von entzündlichen erkrankungen durch elektrische stimulation des vagus-nervs |
| US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
| CA2676119C (en) | 2007-01-29 | 2021-01-19 | Simon Fraser University | Transvascular nerve stimulation apparatus and methods |
| WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
| US20090239901A1 (en) * | 2008-03-19 | 2009-09-24 | Merouane Bencherif | Method and compositions for treatment of cerebral malaria |
| US9211409B2 (en) | 2008-03-31 | 2015-12-15 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of T-cell activity |
| US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
| ES2452484T3 (es) | 2008-11-18 | 2014-04-01 | Setpoint Medical Corporation | Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria |
| TW201031664A (en) | 2009-01-26 | 2010-09-01 | Targacept Inc | Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide |
| US8788034B2 (en) | 2011-05-09 | 2014-07-22 | Setpoint Medical Corporation | Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
| US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
| CN102573986B (zh) | 2009-06-09 | 2016-01-20 | 赛博恩特医疗器械公司 | 用于无导线刺激器的具有袋部的神经封套 |
| US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
| WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
| EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
| US20110268809A1 (en) | 2010-04-28 | 2011-11-03 | Paul Andrew Brinkley | Nicotine-Containing Pharmaceutical Compositions |
| US20110274628A1 (en) | 2010-05-07 | 2011-11-10 | Borschke August J | Nicotine-containing pharmaceutical compositions |
| US12172017B2 (en) | 2011-05-09 | 2024-12-24 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| US20130078307A1 (en) | 2011-09-22 | 2013-03-28 | Niconovum Usa, Inc. | Nicotine-containing pharmaceutical composition |
| US9907748B2 (en) | 2011-10-21 | 2018-03-06 | Niconovum Usa, Inc. | Excipients for nicotine-containing therapeutic compositions |
| US9763928B2 (en) | 2012-02-10 | 2017-09-19 | Niconovum Usa, Inc. | Multi-layer nicotine-containing pharmaceutical composition |
| AU2013230648B2 (en) | 2012-03-05 | 2017-06-15 | Lungpacer Medical Inc. | Transvascular nerve stimulation apparatus and methods |
| US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
| CN104684614B (zh) | 2012-06-21 | 2017-10-17 | 西蒙·弗雷泽大学 | 经血管的膈膜起搏系统及使用方法 |
| RU2514007C1 (ru) * | 2012-10-04 | 2014-04-27 | Государственное научное учреждение Северо-Кавказский зональный научно-исследовательский ветеринарный институт (ГНУ СКЗНИВИ) Российской академии сельскохозяйственных наук | Протистоцидная активность 2-(4,5-дихлоримидазолил-1)-5 нитропиридина |
| US20140255452A1 (en) | 2013-03-11 | 2014-09-11 | Niconovum Usa, Inc. | Method and apparatus for differentiating oral pouch products |
| EP3760276B1 (en) | 2013-11-22 | 2023-08-30 | Lungpacer Medical Inc. | Apparatus for assisted breathing by transvascular nerve stimulation |
| JP6537517B2 (ja) | 2014-01-21 | 2019-07-03 | ラングペーサー メディカル インコーポレイテッドＬｕｎｇｐａｃｅｒ Ｍｅｄｉｃａｌ Ｉｎｃ． | 多電極神経ペーシングの最適化のためのシステムおよび関連する方法 |
| US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
| WO2016126807A1 (en) | 2015-02-03 | 2016-08-11 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
| US20170165252A1 (en) | 2015-12-10 | 2017-06-15 | Niconovum Usa Inc. | Protein-enriched therapeutic composition |
| US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
| WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
| US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
| CN114904142A (zh) | 2016-01-20 | 2022-08-16 | 赛博恩特医疗器械公司 | 迷走神经刺激的控制 |
| US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
| CN107473982B (zh) * | 2016-06-08 | 2020-01-14 | 四川大学 | 端位取代高烯丙基胺衍生物及其制备方法和用途 |
| US10293164B2 (en) | 2017-05-26 | 2019-05-21 | Lungpacer Medical Inc. | Apparatus and methods for assisted breathing by transvascular nerve stimulation |
| CN111163834A (zh) | 2017-06-30 | 2020-05-15 | 隆佩瑟尔医疗公司 | 用于预防、减轻和/或治疗认知损伤的装置 |
| US10195429B1 (en) | 2017-08-02 | 2019-02-05 | Lungpacer Medical Inc. | Systems and methods for intravascular catheter positioning and/or nerve stimulation |
| US10940308B2 (en) | 2017-08-04 | 2021-03-09 | Lungpacer Medical Inc. | Systems and methods for trans-esophageal sympathetic ganglion recruitment |
| EP3668402B1 (en) | 2017-08-14 | 2024-07-31 | Setpoint Medical Corporation | Vagus nerve stimulation pre-screening test |
| US20190175908A1 (en) | 2017-12-11 | 2019-06-13 | Lungpacer Medical Inc. | Systems and methods for strengthening a respiratory muscle |
| EP3807260B1 (en) | 2018-06-15 | 2024-09-18 | R. J. Reynolds Tobacco Company | Purification of nicotine |
| US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
| EP3877043B1 (en) | 2018-11-08 | 2025-04-23 | Lungpacer Medical Inc. | Stimulation systems and related user interfaces |
| AU2020272128B9 (en) | 2019-04-12 | 2025-11-20 | Setpoint Medical Corporation | Vagus nerve stimulation to treat neurodegenerative disorders |
| WO2020232333A1 (en) | 2019-05-16 | 2020-11-19 | Lungpacer Medical Inc. | Systems and methods for sensing and stimulation |
| US11771900B2 (en) | 2019-06-12 | 2023-10-03 | Lungpacer Medical Inc. | Circuitry for medical stimulation systems |
| JP2023526080A (ja) | 2020-05-21 | 2023-06-20 | ザ・フェインステイン・インスティチュート・フォー・メディカル・リサーチ | 迷走神経刺激のためのシステムおよび方法 |
| WO2022245878A1 (en) | 2021-05-17 | 2022-11-24 | Setpoint Medical Corporation | Neurostimulation parameter authentication and expiration system for neurostimulation |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5212188A (en) * | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
| US5852041A (en) * | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
| WO1995029892A1 (en) * | 1994-04-28 | 1995-11-09 | The Du Pont Merck Pharmaceutical Company | Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents |
| US5597919A (en) * | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
| US5604231A (en) * | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
| US5616707A (en) * | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
| US5583140A (en) * | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
| US5616716A (en) * | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
| ATE416164T1 (de) * | 1996-04-23 | 2008-12-15 | Targacept Inc | Pharmazeutische zusammenstellungen zur prävention und behandlung von zns-erkrankungen |
| US5663356A (en) * | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
| ZA9711092B (en) * | 1996-12-11 | 1999-07-22 | Smithkline Beecham Corp | Novel compounds. |
| US5861423A (en) * | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
| US5811442A (en) * | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
| WO1998047899A1 (en) * | 1997-04-24 | 1998-10-29 | Ortho-Mcneil Corporation, Inc. | Substituted pyrrolopyridines useful in the treatment of inflammatory diseases |
-
1999
- 1999-04-20 US US09/295,181 patent/US6166048A/en not_active Expired - Fee Related
-
2000
- 2000-04-20 DK DK00926142T patent/DK1171127T3/da active
- 2000-04-20 WO PCT/US2000/010551 patent/WO2000062767A2/en not_active Ceased
- 2000-04-20 DE DE60022637T patent/DE60022637T2/de not_active Expired - Lifetime
- 2000-04-20 KR KR1020017013390A patent/KR100816898B1/ko not_active Expired - Fee Related
- 2000-04-20 BR BR0009869-8A patent/BR0009869A/pt not_active IP Right Cessation
- 2000-04-20 JP JP2000611904A patent/JP2002542188A/ja active Pending
- 2000-04-20 MX MXPA01010635A patent/MXPA01010635A/es active IP Right Grant
- 2000-04-20 AU AU44719/00A patent/AU4471900A/en not_active Abandoned
- 2000-04-20 AT AT00926142T patent/ATE304355T1/de active
- 2000-04-20 EP EP00926142A patent/EP1171127B1/en not_active Expired - Lifetime
- 2000-04-20 CA CA2370206A patent/CA2370206C/en not_active Expired - Fee Related
- 2000-04-20 ES ES00926142T patent/ES2251995T3/es not_active Expired - Lifetime
- 2000-09-06 US US09/656,284 patent/US6489349B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542188A5 (enExample) | ||
| CA2370206A1 (en) | Pharmaceutical compositions for inhibition of cytokine production and secretion | |
| RU2348627C2 (ru) | Ингибиторы тирозинкиназ | |
| CA2436980A1 (en) | Amido ether substituted imidazoquinolines | |
| ZA992951B (en) | N-substituted aminotetralins as ligands for the neuropeptide Y Y5 receptor useful in the treatment of obesity and other disorders. | |
| JP2004521087A5 (enExample) | ||
| WO2003037271A3 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
| JP2003500442A5 (enExample) | ||
| JP2005531607A5 (enExample) | ||
| RU2003114752A (ru) | Лечение желудочно-кишечных стромальных опухолей | |
| EP1731141A3 (en) | Gastric acid secretion inhibiting composition | |
| RU2003132687A (ru) | Лечение диабета типа 2 ингибиторами дипептидилпептидазы iv | |
| JP2001526218A5 (enExample) | ||
| WO2001064200A3 (en) | Use of pdgf receptor tyrosine kinase inhibitors for the treatment of diabetic nephropathy | |
| JP2009538873A5 (enExample) | ||
| PH12014500937A1 (en) | 5-ht 1a receptor substype agonist | |
| JP2002519425A5 (enExample) | ||
| JP2003521514A5 (enExample) | ||
| EP1149842A3 (en) | Somatostatin antagonists and agonists that act at the sst subtype 2 receptor | |
| JP2005511594A5 (enExample) | ||
| CA2405971A1 (en) | New piperazine and piperidine compounds | |
| JP2002506864A5 (enExample) | ||
| JP2003508543A5 (enExample) | ||
| RU2000104870A (ru) | Производные фталазина и терапевтические средства для эректильной дисфункции | |
| JP2002521468A5 (enExample) |